NEW YORK (GenomeWeb News) — Pikamab said today that it has exclusively licensed a pair of US patents from the Hospital for Special Surgery in New York to develop a theranostic product to help guide drug development and patient treatment for lupus and lupus nephritis.

The first US patent, No. 5,830,652, provides methods for determining the severity of lupus and lupus nephritis by correlating to the functional polymorphisms in FcGR genes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.